Eliglustat (Cerdelga®, Genzyme Corp. Cambridge, MA, USA) is an approved drug for a non-neurological type of Gaucher disease. Herein, we describe the total synthesis of eliglustat 1 starting from readily available 1,4-benzodioxan-6-carbaldehyde via Sharpless asymmetric dihydroxylation and diastereoselective amination of chiral para-methoxycinnamyl benzyl ethers using chlorosulfonyl isocyanate as the key steps. Notably, the reaction between syn-1,2-dibenzyl ether 6 and chlorosulfonyl isocyanate in the mixture of toluene and hexane (10:1) afforded syn-1,2-amino alcohol 5 at a 62% yield with a diastereoselectivity > 20:1. This observation can be explained by competition between the SNi and the SN1 mechanisms, leading to the retention of stereochemistry.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029353PMC
http://dx.doi.org/10.3390/molecules27082603DOI Listing

Publication Analysis

Top Keywords

total synthesis
8
synthesis eliglustat
8
diastereoselective amination
8
amination chiral
8
chlorosulfonyl isocyanate
8
eliglustat diastereoselective
4
chiral -methoxycinnamyl
4
-methoxycinnamyl benzyl
4
benzyl ether
4
ether eliglustat
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!